Cited by 171Electromagnetic Fields and Biological EffectsMicrobial Inactivation MethodsCancer Cells and Metastasis

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index; 3 of the 15 sources its claims cite were checked for support.

Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs

Open access

Abstract

Tumor treating fields (TTFields) are low intensity, intermediate frequency, alternating electric fields used to treat cancerous tumors. This novel treatment modality effectively inhibits the growth of solid tumors in vivo and has shown promise in pilot clinical trials in patients with advanced stage solid tumors. TTFields were tested for their potential to inhibit metastatic spread of solid tumors to the lungs in two animal models: (1) Mice injected with malignant melanoma cells (B16F10) into the tail vein, (2) New Zealand White rabbits implanted with VX-2 tumors within the kidney capsule. Mice and rabbits were treated using two-directional TTFields at 100-200 kHz. Animals were either monitored for survival, or sacrificed for pathological and histological analysis of the lungs. The total number of lung surface metastases and the absolute weight of the lungs were both significantly lower in TTFields treated mice then in sham control mice. TTFields treated rabbits survived longer than sham control animals. This extension in survival was found to be due to an inhibition of metastatic spread, seeding or growth in the lungs of TTFields treated rabbits compared to controls. Histologically, extensive peri- and intra-tumoral immune cell infiltration was seen in TTFields treated rabbits only. These results raise the possibility that in addition to their proven inhibitory effect on the growth of solid tumors, TTFields may also have clinical benefit in the prevention of metastatic spread from primary tumors.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

In two animal models, TTFields reduced lung metastases and prolonged survival in rabbits with VX-2 kidney tumors. The effects may involve direct inhibition of metastatic cells and/or a systemic anti-tumor immune response.

Key findings

  • In mice, 7 days of TTFields reduced surface lung metastases versus sham controls (1.5 ± 1 vs. 10.3 ± 8.4; P < 0.01) and lowered lung weight (212 ± 10 vs. 253 ± 20 mg; P < 0.01). After 1 week of recovery, total metastases were similar (18 ± 12 vs. 17 ± 15; P = 0.87), but size distribution differed significantly (P < 0.05), with more large metastases in controls and more small metastases in treated mice.
  • In rabbits, TTFields reduced primary kidney tumor volume after treatment (29.0 ± 18.5 vs. 61.1 ± 38.5 cm³; P = 0.0011) and daily growth rate (1.2 ± 1.1 vs. 3.5 ± 3.2; P = 0.003). Median survival was 70 days in treated rabbits versus 57 days in controls (Log-Rank P < 0.05).
  • Rabbit lung metastases were lower when treatment began before day 14 from implantation (n = 12; Fig. 6c; the text reports this as significant while listing P > 0.05), with a trend toward fewer large metastases >3 mm (P = 0.11); no difference was seen when treatment started later. Histology showed fewer metastases per cross-section (11.8 vs. 23.2), smaller mean diameter (1.4 mm vs. 6.2 mm), greater mononuclear infiltration (score 2.0 vs. 1.4), and increased CD4, CD8, and CD45 T-cell counts in TTFields-treated rabbits.

Methods

  • Two animal models were used: female C57BL/6 mice (n = 35) injected IV with B16F10 melanoma and treated with two-directional 100 kHz TTFields for 7 days; and New Zealand White rabbits implanted with VX-2 tumor fragments under the kidney capsule and treated with two-directional 200 kHz TTFields for 5 weeks.
  • Outcomes included mouse lung surface metastases and lung weights at 1 or 7 days after treatment; rabbit MRI tumor volume, survival, and histological/immunohistochemical analysis of lung metastases.
  • Statistical analysis used Student’s t-test, Chi-squared test, Log-Rank test, and a semi-quantitative score (0–5) for immune cell infiltration.

Limitations

  • The paper states that the immune marker profile is not sufficient to prove a tumor-antigen-specific immune reaction, and that the microtubule/migration hypothesis was not directly tested; future experiments are warranted.
  • The paper presents several possible explanations for reduced rabbit lung metastases—lower primary tumor load, inhibited migration into circulation, and systemic immune activation—without directly distinguishing among them.
  • Evident from the text: this is a preclinical animal study only, with small subgroup samples (e.g., n = 12 for early-treatment lung metastasis analysis), and one reported result is internally inconsistent (“significantly lower” with P > 0.05).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s10585-009-9262-y

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Placement of electrodes on mice (a) and rabbits (b). The four insulated electrodes were attached to the skin using hydrogel after depilation. The electrodes were wrapped with leucoplast and electrodes wires were connected to the TTFields generating system or to the sham control system. The four electrodes were functionally divided into two pairs each generating one field direction through the animal. The electrode pairs were placed so as to create two perpendicular field directions at the center of body. Sham electrodes were placed in the same configuration
Fig. 1 Placement of electrodes on mice (a) and rabbits (b). The four insulated electrodes were attached to the skin using hydrogel after depilation. The electrodes were wrapped with leucoplast and electrodes wires were connected to the TTFields generating system or to the sham control system. The four electrodes were functionally divided into two pairs each generating one field direction through the animal. The electrode pairs were placed so as to create two perpendicular field directions at the center of body. Sham electrodes were placed in the same configurationCC BY-NC · PubMed Central
Fig. 2 Malignant melanoma metastases as seen on the surface of the lungs of mice treated with TTFields. Exemplary photos of lungs of mice treated with TTFields (a) or sham control (b) are shown after removal of the pulmonary blood by perfusion with saline. Average number of surface metastases (±SD) in treated and control mice (c). Average lung weight (±SD) of treated and control mice
Fig. 2 Malignant melanoma metastases as seen on the surface of the lungs of mice treated with TTFields. Exemplary photos of lungs of mice treated with TTFields (a) or sham control (b) are shown after removal of the pulmonary blood by perfusion with saline. Average number of surface metastases (±SD) in treated and control mice (c). Average lung weight (±SD) of treated and control miceCC BY-NC · PubMed Central
Fig. 3 Metastases number and size distribution in mice treated with TTFields (open bars) and sham control (closed bars). The mice were treated for 7 days followed by 7 days of recovery
Fig. 3 Metastases number and size distribution in mice treated with TTFields (open bars) and sham control (closed bars). The mice were treated for 7 days followed by 7 days of recoveryCC BY-NC · PubMed Central
Fig. 4 T1 weighted MRI images (post gadolinium) of the maximal cross-sectional area of a TTFields treated (a) versus sham control tumor (b) in rabbit kidneys. Arrows indicate tumor location. Scale bar 1 cm
Fig. 4 T1 weighted MRI images (post gadolinium) of the maximal cross-sectional area of a TTFields treated (a) versus sham control tumor (b) in rabbit kidneys. Arrows indicate tumor location. Scale bar 1 cmCC BY-NC · PubMed Central
Fig. 5 Kaplan–Meier survival curve of rabbits treated with TTFields (n = 23; red line) versus sham controls (n = 20; black line). The median survivals of 70 vs. 57 days, respectively, are indicated by dotted lines
Fig. 5 Kaplan–Meier survival curve of rabbits treated with TTFields (n = 23; red line) versus sham controls (n = 20; black line). The median survivals of 70 vs. 57 days, respectively, are indicated by dotted linesCC BY-NC · PubMed Central
Fig. 6 Exemplary photos of surface lung metastases in TTFields treated (a) versus sham control rabbits (b). Treatment was initiated on day 12 from implantation of the kidney tumor. The average total number (±SD) of surface metastases (c) and the average number of large metastases (±SD) (d) in control versus treated rabbits
Fig. 6 Exemplary photos of surface lung metastases in TTFields treated (a) versus sham control rabbits (b). Treatment was initiated on day 12 from implantation of the kidney tumor. The average total number (±SD) of surface metastases (c) and the average number of large metastases (±SD) (d) in control versus treated rabbitsCC BY-NC · PubMed Central
Fig. 7 Discrete intra-tumoral infiltration of CD45 positive T cells in control tumours (a) and abundant intra-tumoral CD45 positive T cells in TTFields treated tumours (b). Scale bar 100 μm
Fig. 7 Discrete intra-tumoral infiltration of CD45 positive T cells in control tumours (a) and abundant intra-tumoral CD45 positive T cells in TTFields treated tumours (b). Scale bar 100 μmCC BY-NC · PubMed Central

Verification

Claims the paper makes

23 Own result · 11 Own interpretation · 8 Not checked yet · 4 Own method · 1 Partly supported · accuracy not yet measured

Verify all 12 references — free account

Show all 30 claims

  • Probably not a substantial claim. 9
  • It may state two separate claims as one. 10
  • The quote only partly states this claim. 1
17 of 17
  • The paper relies on this without support.

    Little is known about the effect of TTFields on the metastatic spread of solid tumors.

    “Yet, little is know about the effect of TTFields on the metastatic spread of solid tumors.”
  • The authors state this as an assumption.

    The activation of the immune response in the rabbits' lungs was mediated by the TTFields treatment.

    “Assuming that the activation of the immune response in the rabbits’ lungs was mediated by the TTFields treatment”
2 of 2

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. Sardari N, Colpaert C (2007) Lung metastases: epidemiology, clinical presentation and imaging. In: Schil P (ed) Lung metastases and isolated lung perfusion. Nova Science Publishers Inc., New York, pp 3–25

Cited by

Sorted by citations

See all 171

Metadata

Authors
Kirson, E. D., Giladi, M., Gurvich, Z., Itzhaki, A., Mordechovich, D., Schneiderman, R. S., Wasserman, Y., Ryffel, B., Goldsher, D., & Palti, Y.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Rambam Health Care Campus (IL)
Corresponding author
Kirson, Eilon D.
Venue
Clinical & Experimental Metastasis
Published
2009-04-23
Volume
26
Issue
7
Pages
633-640
ISSN
  • 0262-0898 (ISSN-L)
  • 1573-7276
OpenAlex
W2168283594
Cited by
171
References
23
Citations by year
2026: 5 · 2025: 12 · 2024: 14 · 2023: 12 · 2022: 19 · 2021: 14 · 2020: 16 · 2019: 12 · 2018: 10 · 2017: 7 · 2016: 14 · 2015: 8 · 2014: 8 · 2013: 8 · 2012: 3
FWCI
2.37
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Clinical & Experimental Metastasis (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biophysics › Electromagnetic Fields and Biological Effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Microbial Inactivation Methods
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
tumor treating fields, AC electric field, lung metastasis, melanoma, tumor growth inhibition, immune cell infiltration, survival extension, cancer prevention
MeSH terms
Animals, Disease Models, Animal, Electricity, Female, Lung Neoplasms, Melanoma, Mice, Inbred C57BL, Neoplasm Metastasis, Neoplasm Transplantation, Rabbits, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review